These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23482748)

  • 21. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
    Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
    Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70(S6K) in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB.
    Varma S; Khandelwal RL
    Biochim Biophys Acta; 2007 Jan; 1770(1):71-8. PubMed ID: 16952420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
    Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
    PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
    Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
    Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of fludrocortisone on the uterine receptivity partially mediated by ERK1/2-mTOR pathway.
    Hesam Shariati MB; Seghinsara AM; Shokrzadeh N; Niknafs B
    J Cell Physiol; 2019 Nov; 234(11):20098-20110. PubMed ID: 30968418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
    Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
    Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX; Yang X; Sreejayan N; Ren J
    Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
    Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
    Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
    Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
    Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism.
    Osman AM; van Loveren H
    J Appl Toxicol; 2014 Dec; 34(12):1361-7. PubMed ID: 24375594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the mTORC2 and chaperone pathways to treat leukemia.
    Zhang F; Lazorchak AS; Liu D; Chen F; Su B
    Blood; 2012 Jun; 119(25):6080-8. PubMed ID: 22566604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI3K/mTOR signaling pathways in medulloblastoma.
    Mohan AL; Friedman MD; Ormond DR; Tobias M; Murali R; Jhanwar-Uniyal M
    Anticancer Res; 2012 Aug; 32(8):3141-6. PubMed ID: 22843885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.
    Wang X; Beugnet A; Murakami M; Yamanaka S; Proud CG
    Mol Cell Biol; 2005 Apr; 25(7):2558-72. PubMed ID: 15767663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.